SG11202104951RA - Combination treatment of nafld and nash - Google Patents
Combination treatment of nafld and nashInfo
- Publication number
- SG11202104951RA SG11202104951RA SG11202104951RA SG11202104951RA SG11202104951RA SG 11202104951R A SG11202104951R A SG 11202104951RA SG 11202104951R A SG11202104951R A SG 11202104951RA SG 11202104951R A SG11202104951R A SG 11202104951RA SG 11202104951R A SG11202104951R A SG 11202104951RA
- Authority
- SG
- Singapore
- Prior art keywords
- nafld
- nash
- combination treatment
- treatment
- combination
- Prior art date
Links
- 238000011284 combination treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862768226P | 2018-11-16 | 2018-11-16 | |
| PCT/US2019/061159 WO2020102337A1 (en) | 2018-11-16 | 2019-11-13 | Combination treatment of nafld and nash |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104951RA true SG11202104951RA (en) | 2021-06-29 |
Family
ID=68835315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104951RA SG11202104951RA (en) | 2018-11-16 | 2019-11-13 | Combination treatment of nafld and nash |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200155650A1 (en) |
| EP (1) | EP3880185A1 (en) |
| JP (1) | JP2022507644A (en) |
| KR (1) | KR20210092754A (en) |
| CN (1) | CN113301889A (en) |
| AU (1) | AU2019378845A1 (en) |
| BR (1) | BR112021009038A2 (en) |
| CA (1) | CA3118961A1 (en) |
| EA (1) | EA202191379A1 (en) |
| IL (1) | IL283200A (en) |
| MX (1) | MX2021005724A (en) |
| SG (1) | SG11202104951RA (en) |
| WO (1) | WO2020102337A1 (en) |
| ZA (1) | ZA202103188B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA120756C2 (en) | 2014-03-20 | 2020-02-10 | Сімабей Терапьютікс, Інк. | Treatment of intrahepatic cholestatic diseases |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2022232168A1 (en) * | 2021-04-27 | 2022-11-03 | Aardvark Therapeutics, Inc. | Combination of bitter receptor agonist and gut-signaling compound |
| WO2024059480A2 (en) * | 2022-09-12 | 2024-03-21 | Eli Lilly And Company | A gip/glp1 for use in therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0414268B8 (en) | 2003-09-19 | 2021-05-25 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids, analogs, and pharmaceutical compositions |
| JO3006B1 (en) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | Novel Lysine Salts of 4-((Phenoxy Alkyl)Thio)-Phenoxy Acetic Acid Derivatives |
| US10272058B2 (en) * | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| DK3129018T3 (en) | 2014-04-11 | 2020-01-20 | Cymabay Therapeutics Inc | Treatment of NAFLD and NASH |
| KR20190124704A (en) * | 2017-01-24 | 2019-11-05 | 마크레젠, 인크. | Treatment of age-related macular degeneration and other eye diseases using apolipoprotein mimetics |
-
2019
- 2019-11-13 KR KR1020217017115A patent/KR20210092754A/en unknown
- 2019-11-13 AU AU2019378845A patent/AU2019378845A1/en not_active Abandoned
- 2019-11-13 JP JP2021526777A patent/JP2022507644A/en active Pending
- 2019-11-13 WO PCT/US2019/061159 patent/WO2020102337A1/en unknown
- 2019-11-13 MX MX2021005724A patent/MX2021005724A/en unknown
- 2019-11-13 BR BR112021009038-0A patent/BR112021009038A2/en not_active Application Discontinuation
- 2019-11-13 US US16/682,408 patent/US20200155650A1/en not_active Abandoned
- 2019-11-13 SG SG11202104951RA patent/SG11202104951RA/en unknown
- 2019-11-13 CN CN201980089276.2A patent/CN113301889A/en active Pending
- 2019-11-13 EP EP19817481.5A patent/EP3880185A1/en not_active Withdrawn
- 2019-11-13 CA CA3118961A patent/CA3118961A1/en active Pending
- 2019-11-13 EA EA202191379A patent/EA202191379A1/en unknown
-
2021
- 2021-05-11 ZA ZA2021/03188A patent/ZA202103188B/en unknown
- 2021-05-13 IL IL283200A patent/IL283200A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3118961A1 (en) | 2020-05-22 |
| EP3880185A1 (en) | 2021-09-22 |
| BR112021009038A2 (en) | 2021-08-10 |
| AU2019378845A1 (en) | 2021-06-03 |
| JP2022507644A (en) | 2022-01-18 |
| WO2020102337A1 (en) | 2020-05-22 |
| MX2021005724A (en) | 2021-07-21 |
| US20200155650A1 (en) | 2020-05-21 |
| AU2019378845A8 (en) | 2021-06-17 |
| IL283200A (en) | 2021-06-30 |
| EA202191379A1 (en) | 2021-08-06 |
| CN113301889A (en) | 2021-08-24 |
| KR20210092754A (en) | 2021-07-26 |
| ZA202103188B (en) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281093A (en) | Combinations for treatment of nash/nafld and related diseases | |
| IL283200A (en) | Combination treatment of nafld and nash | |
| SG11201608077PA (en) | Treatment of nafld and nash | |
| IL275626A (en) | Surface treatment compositions and methods | |
| IL266519A (en) | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| FI3773689T3 (en) | Antigenic peptides for prevention and treatment of cancer | |
| IL272937A (en) | Compositions and methods for the treatment of fibrotic diseases | |
| IL280348A (en) | Surface treatment compositions and methods | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| IL276792A (en) | Inhaler and methods of use thereof | |
| ZA202002669B (en) | Prevention and treatment of graft-versus-host-disease with defensins | |
| GB202306894D0 (en) | Therapeutic and prohylactic use of microoganisms | |
| PT3708174T (en) | Methods and treatment of trauma | |
| EP3381459A4 (en) | Prophylactic and/or therapeutic agent for nafld/nash | |
| IL280262A (en) | Compositions and methods for the treatment of cancer | |
| GB201605127D0 (en) | Composition and methods of treatment | |
| GB2590245B (en) | Encapsulated antimicrobials and related methods of treatment | |
| GB201815000D0 (en) | Treatment of hypothroidism and related conditions | |
| GB201815694D0 (en) | Prevention and treatment of cancer | |
| GB201810925D0 (en) | Compositions and methods of treatment | |
| GB201809946D0 (en) | Prevention and treatment of cancer | |
| IL280868A (en) | Compositions and methods for treatment of acute lung injury | |
| IL282686A (en) | Treatment and prevention of premature ejaculation (pe) | |
| IL282671A (en) | Therapeutic methods and compositions |